ANDA 211139, held by Amneal Pharms. Amphetamine Sulfate.
As of Nov 16, 2026, ANDA 211139 (Amphetamine Sulfate), held by Amneal Pharms, was first approved by FDA on Sep 26, 2018, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amphetamine sulfate tablets, USP 5 mg and 10 mg are indicated for: 1. Narcolepsy 2. Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 26, 2018 | Original application | Approved |
| Amphetamine Sulfate5MG · tablet;oral | Amphetamine Sulfate | Rx |
| Amphetamine Sulfate10MG · tablet;oral | Amphetamine Sulfate | Rx |
| Sep 26, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 16, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 11, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 25, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 10, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 26, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters